

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	4618892
<b>Application Number:</b>	10821389
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1599
<b>Title of Invention:</b>	Calcium channel inhibitors comprising benzhydryl spaced from piperazine
<b>First Named Inventor/Applicant Name:</b>	Terrance P. Snutch
<b>Customer Number:</b>	25225
<b>Filer:</b>	Kate H. Murashige
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	381092000624
<b>Receipt Date:</b>	15-JAN-2009
<b>Filing Date:</b>	09-APR-2004
<b>Time Stamp:</b>	19:45:31
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	6196
Deposit Account	031952
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	381092000624_TRANS.pdf	27918 24b5a7eb380704882264257991e1ce13b124218	no	1
<b>Warnings:</b>					
<b>Information:</b>					
2	Information Disclosure Statement Letter	381092000624_IDS.pdf	24253 7b25f8ec3a3b627497ca74eb4b9c5c5c3c13212ac	no	3
<b>Warnings:</b>					
<b>Information:</b>					
3	Information Disclosure Statement (IDS) Filed (5B/08)	381092000624_SB08.pdf	28645 0064572abc60206d8c9027e8180352271725451	no	1
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
4	NPL Documents	US20080929NOA10928564.pdf	558473 26ade386dc191f9ccacba085c26e67c05e636d	no	14
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	MIHELE2002Farmacia78_STNse arch.pdf	42720 85431f1f1a634b31a136ba858d1130240808acdf	no	2
<b>Warnings:</b>					
<b>Information:</b>					
6	Fee Worksheet (PTO-06)	fee-info.pdf	30053 499ac11e3ed426c7675f83296a80bc5c737d0c0c	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			712062		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.